Emerging therapies, particularly GLP-1 receptor agonists like semaglutide, have shown promise in reducing cardiovascular risk and promoting weight loss in obese patients without diabetes [134], but evidence in KTRs remains limited. This evidence concerns the gene GLP1R and diabetes mellitus.